TRANSURETHRAL NEEDLE ABLATION VERSUS TRANSURETHRAL RESECTION OF THE PROSTATE FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA: 5-YEAR RESULTS OF A PROSPECTIVE, RANDOMIZED, MULTICENTER CLINICAL TRIAL

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Jun 2004TRANSURETHRAL NEEDLE ABLATION VERSUS TRANSURETHRAL RESECTION OF THE PROSTATE FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA: 5-YEAR RESULTS OF A PROSPECTIVE, RANDOMIZED, MULTICENTER CLINICAL TRIAL BRIAN HILL, WILLIAM BELVILLE, REGINALD BRUSKEWITZ, MUTA ISSA, RAMON PEREZ-MARRERO, CLAUS ROEHRBORN, MARTHA TERRIS, and MICHAEL NASLUND BRIAN HILLBRIAN HILL , WILLIAM BELVILLEWILLIAM BELVILLE , REGINALD BRUSKEWITZREGINALD BRUSKEWITZ , MUTA ISSAMUTA ISSA , RAMON PEREZ-MARRERORAMON PEREZ-MARRERO , CLAUS ROEHRBORNCLAUS ROEHRBORN , MARTHA TERRISMARTHA TERRIS , and MICHAEL NASLUNDMICHAEL NASLUND View All Author Informationhttps://doi.org/10.1097/01.ju.0000127761.87421.a0AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We report the 5-year efficacy and safety of transurethral needle ablation of the prostate (TUNA) compared to transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Materials and Methods: A total of 121 men 50 years or older with LUTS secondary to BPH a minimum of 3 months in duration were enrolled in this prospective, randomized clinical trial at 7 medical centers across the United States. Of the participants 65 (54%) were randomly selected to receive TUNA and 56 (46%) were selected to receive TURP. International Prostate Symptom Score, quality of life, peak urinary flow rate, post-void residual urinary volume, and prostate size and configuration were evaluated before the procedure and then annually for 5 years after the procedure. Adverse events were also recorded throughout the study. Results: Improvement from baseline for TUNA and TURP retained statistical significance at each interval for International Prostate Symptom Score, quality of life and peak flow rate. Post-void residual volume was statistically significant at all time points for TURP and at year 5 for TUNA. The TURP group reported 41% retrograde ejaculation, while the TUNA group reported none. The incident of erectile dysfunction, incontinence and stricture formation was also greater in TURP than in TUNA cases with significantly fewer adverse events for TUNA than for TURP. Conclusions: The results of this study demonstrate stable treatment outcomes after 5 years of followup and suggest that TUNA is an attractive treatment option for men with LUTS due to BPH. References 1 : The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol1993; 150: 85. Link, Google Scholar 2 : Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology1997; 49: 839. Google Scholar 3 : Prospective study of men with clinical benign prostate hyperplasia treated with alfuzosin by general practitioners: 1-year results. Urology1996; 48: 731. Google Scholar 4 : Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice. Prostate Cancer Prostatic Dis1998; 1: 276. Google Scholar 5 : The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med2003; 349: 2387. Google Scholar 6 : Current status of thermotherapy of the prostate. J Urol1997; 157: 430. Link, Google Scholar 7 : Initial human clinical experience with diode laser interstitial treatment of benign prostatic hyperplasia. Urology1996; 48: 223. Google Scholar 8 : Transurethral water-induced thermotherapy for the treatment of benign prostatic hyperplasia: a prospective multicenter clinical trial. J Urol2000; 164: 1565. Link, Google Scholar 9 : A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol1998; 159: 1588. Link, Google Scholar 10 : Transurethral needle ablation for benign prostatic hyperplasia: 12-month results of a prospective, multicenter U.S. study. Urology1998; 51: 415. Google Scholar 11 : Transurethral needle ablation of the prostate for treatment of benign prostatic hyperplasia: early clinical experience. Urology1995; 45: 28. Google Scholar 12 : Transurethral needle ablation (TUNA): safety, feasibility, and tolerance of a new office procedure for treatment of benign prostatic hyperplasia. Eur Urol1993; 24: 415. Google Scholar 13 : Transurethral needle ablation (TUNA): thermal gradient mapping and comparison of lesion size in a tissue model and in patients with benign prostatic hyperplasia. Eur Urol1993; 24: 411. Google Scholar 14 : Transurethral needle ablation of the prostate. Urology1997; 50: 167. Google Scholar 15 : Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group Proscar Long-term Efficacy and Safety Study. Urology1999; 54: 670. Google Scholar 16 : Alpha blockade for the treatment of benign prostatic hyperplasia. Urol Clin North Am1995; 22: 375. Google Scholar 17 : Possible mechanisms of action of transurethral needle ablation of the prostate on benign prostatic hyperplasia symptoms: a neurohistochemical study. J Urol1997; 157: 894. Link, Google Scholar 18 : Transurethral needle ablation (TUNA) in benign prostatic hypertrophy: 2-year follow-up. Arch Ital Urol Androl1998; 70: 11. Google Scholar 19 : Transurethral needle ablation of the prostate: a urodynamic based study with 2-year followup. J Urol1997; 158: 1834. Link, Google Scholar 20 : Incidence of erectile dysfunction in men 40 to 69 year old: longitudinal results from the Massachusetts male aging study. J Urol2000; 163: 460. Link, Google Scholar From the Division of Urology, University of Maryland School of Medicine, Baltimore, Maryland, Department of Urology, University of Michigan School of Medicine, Ann Arbor, Michigan, Center for Health Sciences, University of Wisconsin Hospital and Clinics, Madison, Wisconsin, Department of Urology, Emory University School of Medicine, Atlanta, Georgia, Urology Health Center, New Port Richey, Florida, Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, and Department of Urology Stanford and Palo Alto Veterans Affairs Medical Center, Palo Alto, California© 2004 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byMcVary K, Gittelman M, Goldberg K, Patel K, Shore N, Levin R, Pliskin M, Beahrs J, Prall D, Kaminetsky J, Cowan B, Cantrill C, Mynderse L, Ulchaker J, Tadros N, Gange S and Roehrborn C (2021) Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic HyperplasiaJournal of Urology, VOL. 206, NO. 3, (715-724), Online publication date: 1-Sep-2021.Rosario D, Phillips J and Chapple C (2018) Durability and Cost-Effectiveness of Transurethral Needle Ablation of the Prostate as an Alternative to Transurethral Resection of the Prostate When α-Adrenergic Antagonist Therapy FailsJournal of Urology, VOL. 177, NO. 3, (1047-1051), Online publication date: 1-Mar-2007.NASLUND M, CARLSON A and WILLIAMS M (2018) A COST COMPARISON OF MEDICAL MANAGEMENT AND TRANSURETHRAL NEEDLE ABLATION FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA DURING A 5-YEAR PERIODJournal of Urology, VOL. 173, NO. 6, (2090-2093), Online publication date: 1-Jun-2005. Volume 171Issue 6 Part 1June 2004Page: 2336-2340 Advertisement Copyright & Permissions© 2004 by American Urological Association, Inc.Keywordsurinary tractprostatic hyperplasiaprostatetransurethral resection of prostateMetricsAuthor Information BRIAN HILL More articles by this author WILLIAM BELVILLE More articles by this author REGINALD BRUSKEWITZ More articles by this author MUTA ISSA More articles by this author RAMON PEREZ-MARRERO More articles by this author CLAUS ROEHRBORN More articles by this author MARTHA TERRIS More articles by this author MICHAEL NASLUND Financial interest and/or other relationship with Glaxo, Merck, Medtronic and Celsion. More articles by this author Expand All Advertisement PDF downloadLoading ...